logo

Seattle Genetics Inc. (SGEN)



Trade SGEN now with
  Date
  Headline
2/7/2020 8:05:57 AM William Blair Is Cutting Seattle Genetics Inc. (SGEN) FY20 Rev. Estimate To 694 M From 753 M
2/7/2020 8:05:21 AM William Blair Is Cutting Seattle Genetics Inc. (SGEN) FY22 Estimate To -1.65 From 0.57
2/7/2020 8:05:00 AM William Blair Is Cutting Seattle Genetics Inc. (SGEN) FY21 Estimate To -2.31 From -0.32
2/7/2020 8:04:44 AM William Blair Is Lowering Seattle Genetics Inc. (SGEN) FY20 Estimate To -3.08 From -1.53
2/7/2020 8:03:16 AM William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform
2/6/2020 4:06:49 PM Seattle Genetics Q4 EPS $0.14 Vs. Loss $0.75 Year Ago
1/31/2020 8:04:33 AM SGEN: EMA Validates MAA For Tucatinib For Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer
1/21/2020 8:06:16 AM Seattle Genetics Achieves Milestone Following EU Approval Of Roche's Polivy For Lymphoma Treatment
12/23/2019 8:02:37 AM Seattle Genetics Submits Tucatinib NDA To FDA For Locally Advanced Or Metastatic HER2-Positive Breast Cancer
12/18/2019 7:38:14 PM FDA Grants Accelerated Approval To Astellas' And Seattle Genetics' PADCEV For Most Common Type Of Bladder Cancer
12/18/2019 8:05:38 AM Seattle Genetics Says FDA Granted Breakthrough Therapy Designation To Tucatinib
12/12/2019 7:13:11 AM William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform